Vertex Pharmaceuticals (VRTX)
411.00
-2.37 (-0.57%)
At close: Jan 14, 2025, 3:59 PM
412.89
0.46%
After-hours Jan 14, 2025, 06:30 PM EST
undefined% (undefined)
| Bid | 381 |
| Market Cap | 105.84B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.9 |
| PE Ratio (ttm) | -216.31 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 420 |
| Volume | 1,045,503 |
| Avg. Volume (20D) | 1,504,250 |
| Open | 411.94 |
| Previous Close | 413.37 |
| Day's Range | 408.09 - 414.50 |
| 52-Week Range | 377.85 - 519.88 |
| Beta | undefined |
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 1991
Employees 5,400
Stock Exchange NASDAQ
Ticker Symbol VRTX
Website https://www.vrtx.com
Analyst Forecast
According to 29 analyst ratings, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $510, which is an increase of 24.09% from the latest price.
Buy 65.52%
Hold 31.03%
Sell 3.45%
Next Earnings Release
Vertex Pharmaceuticals is scheduled to release its earnings on Feb 3, 2025,
during market hours.
Analysts project revenue of $2.78B, reflecting a 10.42% YoY growth and earnings per share of 4.1, making a -2.38% decrease YoY.
Analysts project revenue of $2.78B, reflecting a 10.42% YoY growth and earnings per share of 4.1, making a -2.38% decrease YoY.
3 weeks ago ·
Source
-11.37%
Vertex Pharmaceuticals shares are trading lower. T...
Unlock content with
Pro Subscription
2 months ago ·
Source
-3.77%
Shares of pharmaceutical companies are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.
